EcoDrugPlus

Integrin Subunit Beta 7

Ensembl ID : ENSOTSG00005033009
Gene Symbol: ITGB7
1 Cross references
133 Possible Orthologues:

Integrin, Alpha 2b

Ensembl ID : ENSOTSG00005023007
Gene Symbol: ITGA2B
1 Cross references
178 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSOTSG00005005244
Gene Symbol: ITGA5
1 Cross references
200 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSOTSG00005013875
Gene Symbol: ITGA5
1 Cross references
200 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSOTSG00005035895
Gene Symbol: ITGB1A
1 Cross references
209 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSOTSG00005033080
Gene Symbol: ITGB1A
1 Cross references
209 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSOTSG00005045772
Gene Symbol: ITGB5
1 Cross references
204 Possible Orthologues:

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSOTSG00005025491
Gene Symbol: IRAK4
3 Cross references
200 Possible Orthologues:

Inward Rectifier Potassium Channel 2-Like

Ensembl ID : ENSOTSG00005000414
Gene Symbol: LOC112257877
3 Cross references
201 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSOTSG00005046680
Gene Symbol: IDH1
1 Cross references
227 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSOTSG00005014777
Gene Symbol: IDH1
1 Cross references
227 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSOTSG00005012626
Gene Symbol: IDH1
1 Cross references
227 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).